Umecrine Cognition raises new funds to support clinical development of novel drug candidate GR3027 for hepatic encephalopathy – Phase I clinical trial initiated
March 10, 2016 02:00 ET
|
Karolinska Development AB
The new funds will be used by Umecrine Cognition to conduct a Phase I (first in human) clinical trial with the company’s oral drug candidate GR3027 in 58 healthy volunteers to assess safety,...
437 miljoner i kapitalresning i Karolinska Developments portföljbolag Aprea
March 09, 2016 02:00 ET
|
Karolinska Development AB
Aprea kommer att använda kapitaltillskottet till klinisk utveckling av sin läkemedelskandidat APR-246, ett first in class anti-cancerläkemedel som riktas mot och återaktiverar...
Karolinska Development’s portfolio company Aprea raises SEK 437 million
March 09, 2016 02:00 ET
|
Karolinska Development AB
The new funds will be used by Aprea to advance the clinical development of its lead cancer program, APR-246, a first-in-class anti-cancer compound that targets and re-activates the tumor suppressor...
Karolinska Development portfolio company Akinion Halts Further Development of AKN-028 due to Safety Concerns
March 04, 2016 02:00 ET
|
Karolinska Development AB
Jim Van heusden, CEO of Karolinska Development, said: “Today´s announcement is obviously very disappointing news for patients with acute myeloid leukemia given the great need for improved treatment...
Karolinska Developments portföljbolag Akinion stoppar vidare utveckling av AKN-028 av säkerhetsskäl
March 04, 2016 02:00 ET
|
Karolinska Development AB
Jim Van heusden, VD i Karolinska Development: Det vi annonserat idag är verkligen en besvikelse för patienter med akut myeloisk leukemi med tanke på det stora behovet av förbättrade...
Karolinska Development – Q4 and 2015 Year-End Report – February 2016
February 23, 2016 02:00 ET
|
Karolinska Development AB
Jim Van heusden, CEO, comments: “During the course of 2015 we have made significant progress in executing our new strategy which is designed to transform Karolinska Development into a successful...
Karolinska Development – Delårsrapport för fjärde kvartalet och bokslutskommunikén för 2015
February 23, 2016 02:00 ET
|
Karolinska Development AB
Jim Van heusden, VD, kommenterar: “Under 2015 har vi gjort betydande framsteg när det gäller att implementera vår nya strategi, vilken syftar till att omvandla Karolinska Development till ett...
Karolinska Development – Q4 and 2015 Year-End Report - invitation to conference call and webcast
February 17, 2016 02:00 ET
|
Karolinska Development AB
Please dial in at one of the following numbers a few minutes before the start of the conference call:
From Sweden: +46 (0)8 505 564 74
From the US: +1 855 753 22 30
From the UK: +44 20...
Karolinska Development – Delårsrapport för fjärde kvartalet och bokslutskommunikén för 2015, inbjudan till telefonkonferens och webbpresentation
February 17, 2016 02:00 ET
|
Karolinska Development AB
Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start:
Från Sverige: +46 (0) 8 505 564 74
Från USA: +1 855 753 22 30
Från Storbritannien: +44...
Karolinska Development portfolio company Dilaforette signs clinical collaboration agreement with Arabian Gulf University (Bahrain) for Phase 2 clinical development of sevuparin for Sickle Cell Disease
February 16, 2016 02:00 ET
|
Karolinska Development AB
Dilaforette and AGU’s collaboration will facilitate the development of Dilaforette’s lead candidate, sevuparin, for patients with SCD. AGU will provide up to $1.2 million in non-dilutive funding for...